By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eisai Inc. 

900 Davis Drive
P.O. Box 14505
Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-941-6920 Fax: 919-941-6931

Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit

Key Statistics

Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: 2600
Symbol: ESALF.PK


Company News
Eisai Inc. (ESALF.PK) Release: Meta-Analysis Of Published Trials Supports The Extrapolation Of Antiepileptic Drug Efficacy Data From Adult To Pediatric Patients With Primary Generalized Tonic-Clonic Seizures 4/27/2017 6:58:12 AM
Eisai Inc. (ESALF.PK) Announces Continued Support Of Initiatives For The Elimination Of Lymphatic Filariasis 4/19/2017 8:47:26 AM
Eisai Inc. (ESALF.PK) Release: Halaven (Eribulin) Launches In South Africa For The Treatment Of Women With Advanced Breast Cancer 2/28/2017 8:58:08 AM
Eisai Inc. (ESALF.PK) In-Licenses China Rights For Two Parkinson's Drugs From Orion Corporation 2/23/2017 10:03:03 AM
Eisai Inc. (ESALF.PK) Release: Positive Topline Results Of Large Phase 3 Trial Show Pharma's Lenvatinib Meets Primary Endpoint In Unresectable Hepatocellular Carcinoma 1/25/2017 10:02:18 AM
Eisai Inc. (ESALF.PK) Presents Data On BACE Inhibitor Elenbecestat (E2609) At 9th Clinical Trials On Alzheimer's Disease (CTAD) Meeting 12/12/2016 7:03:29 AM
Eisai Inc. (ESALF.PK) Announces New Analyses And Data On Perampanel At American Epilepsy Society Meeting 12/6/2016 11:37:34 AM
Eisai Inc. (ESALF.PK) Announces Final Results From Phase 3 Open-Label Study Of Rufinamide At American Epilepsy Society Annual Meeting 12/6/2016 6:37:20 AM
Eisai Inc. (ESALF.PK) Initiates Phase 2 Clinical Trial To Evaluate Lemborexant In The Treatment Of Irregular Sleep-Wake Rhythm Disorder (ISWRD) In Dementia Patients 10/31/2016 6:45:40 AM
Now Enrolling: Global Phase 3 Clinical Study To Evaluate Eisai Inc. (ESALF.PK)'s BACE Inhibitor In Early Alzheimer's Disease 10/31/2016 6:44:42 AM